Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avai Bio (AVAI) Common Equity (2018 - 2023)

Avai Bio's Common Equity history spans 5 years, with the latest figure at -$1.4 million for Q4 2023.

  • For Q4 2023, Common Equity fell 159.67% year-over-year to -$1.4 million; the TTM value through Dec 2023 reached -$1.4 million, down 159.67%, while the annual FY2023 figure was -$633259.0, N/A changed from the prior year.
  • Common Equity for Q4 2023 was -$1.4 million at Avai Bio, down from -$991302.0 in the prior quarter.
  • Across five years, Common Equity topped out at $73227.0 in Q3 2020 and bottomed at -$1.4 million in Q4 2023.
  • The 4-year median for Common Equity is -$419825.0 (2022), against an average of -$434106.5.
  • The largest annual shift saw Common Equity tumbled 3015.61% in 2019 before it soared 114.64% in 2020.
  • A 4-year view of Common Equity shows it stood at -$132656.0 in 2019, then surged by 155.2% to $73227.0 in 2020, then tumbled by 836.73% to -$539482.0 in 2022, then crashed by 159.67% to -$1.4 million in 2023.
  • Per Business Quant, the three most recent readings for AVAI's Common Equity are -$1.4 million (Q4 2023), -$991302.0 (Q3 2023), and -$993781.0 (Q2 2023).